Why LifeStance Health Group Zoomed 20% Higher Today
Key Points
This was strongly evidenced by its 21% revenue increase in the first quarter.
Its profitability rocketed even higher.
- 10 stocks we like better than LifeStance Health Group ›
Outpatient mental health services provider LifeStance Health Group (NASDAQ: LFST) was lively on the stock market for all the right reasons on Thursday. The specialized healthcare company reported an impressive beat-and-raise quarter, and investors fell over themselves trying to buy its shares. By the time the dust cleared, LifeStance's equity was up by more than 20%.
Healthy gains
In its first quarter, LifeStance's revenue was $403.5 million. This was a significant (21%) year-over-year improvement in that line item. Net income under generally accepted accounting principles (GAAP) soared, meanwhile, rising from the year-ago tally of $709,000 to $14.2 million, or $0.04 per share.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
That caught more than a few analysts off guard, as those professionals were collectively modeling $387.4 million in revenue and a per-share net income of only $0.01.
In its earnings report, LifeStance quoted CEO Dave Bourdon as saying that "our performance demonstrates that our differentiated model is meeting the societal trend of growing demand for mental healthcare."
Bourdon also cited an outcome study conducted by the company, which found that roughly three-quarters of its patients reported clinically significant improvement in anxiety and depression.
A hot niche at the moment
With this considerable tailwind, LifeStance raised its full-year guidance.
The company now expects to earn revenue of $1.64 billion to $1.68 billion, up from its previous forecast of under $1.62 billion to nearly $1.66 billion. Non-GAAP (adjusted) earnings before interest, taxes, depreciation, and amortization (EBITDA) are expected to be $200 million to $220 million, up from $185 million to $205 million previously.
I'd agree with management's assessment that mental health is a (justifiably) popular segment of the industry just now. With its next-generation services in this niche, LifeStance absolutely has notable growth potential in its future.
Should you buy stock in LifeStance Health Group right now?
Before you buy stock in LifeStance Health Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and LifeStance Health Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $476,034!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,274,109!*
Now, it’s worth noting Stock Advisor’s total average return is 974% — a market-crushing outperformance compared to 206% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 7, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
